Logo of plospathPLoS PathogensSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)View this Article
PLoS Pathog. 2008 Nov; 4(11): e1000214.
Published online 2008 Nov 21. doi:  10.1371/journal.ppat.1000214
PMCID: PMC2581438

A Genetically Hard-Wired Metabolic Transcriptome in Plasmodium falciparum Fails to Mount Protective Responses to Lethal Antifolates

Kami Kim, Editor


Genome sequences of Plasmodium falciparum allow for global analysis of drug responses to antimalarial agents. It was of interest to learn how DNA microarrays may be used to study drug action in malaria parasites. In one large, tightly controlled study involving 123 microarray hybridizations between cDNA from isogenic drug-sensitive and drug-resistant parasites, a lethal antifolate (WR99210) failed to over-produce RNA for the genetically proven principal target, dihydrofolate reductase-thymidylate synthase (DHFR-TS). This transcriptional rigidity carried over to metabolically related RNA encoding folate and pyrimidine biosynthesis, as well as to the rest of the parasite genome. No genes were reproducibly up-regulated by more than 2-fold until 24 h after initial drug exposure, even though clonal viability decreased by 50% within 6 h. We predicted and showed that while the parasites do not mount protective transcriptional responses to antifolates in real time, P. falciparum cells transfected with human DHFR gene, and adapted to long-term WR99210 exposure, adjusted the hard-wired transcriptome itself to thrive in the presence of the drug. A system-wide incapacity for changing RNA levels in response to specific metabolic perturbations may contribute to selective vulnerabilities of Plasmodium falciparum to lethal antimetabolites. In addition, such regulation affects how DNA microarrays are used to understand the mode of action of antimetabolites.

Author Summary

Traditional knowledge of gene regulation, learned largely from non-pathogenic model organisms such as E. coli, yeast, and mice, suggests that RNA for metabolic pathways are regulated in large part by DNA-binding transcriptional factors that are responsive to cellular metabolic needs. We demonstrate that the malaria-causing Plasmodium falciparum parasites, under lethal drug pressure from an antifolate with a known mechanism of action, are incapable of large reproducible changes in RNA levels for the target pathways, or for any other gene throughout the genome. Small RNA changes, possibly informative of perturbed pathways, can be detected in dying parasites. In addition, significant RNA changes are seen when the hard-wired program, governing RNA levels, itself is altered. Our data formally proves that RNA levels for intermediary metabolism in malaria parasites are largely predetermined. We propose that as a parasite with a complex life cycle travels from one largely predictable intracellular biochemical environment to another, such hard-wiring may be sufficient to manage transcript levels for intermediary metabolism without employing sensory functions. Such a system-wide host–parasite difference in gene regulation may create unexpected pharmacological opportunities when important target pathways are rigid in the parasite but dynamically regulated in host cells.


Malaria parasites infect over 300 million people around the world and the most virulent species, Plasmodium falciparum, kills 1–2 million individuals per year [1][3]. The availability of genome-wide DNA microarrays for P. falciparum, has facilitated insights into many complex biological problems. During erythrocytic development, over 3,000 genes are expressed in a cascade of simple, mostly unique, sigmoidal patterns [4][7]. While some genes are expressed at a steady rate, hundreds of genes show at least 30-fold change in expression during the erythrocytic cycle [4]. In addition DNA microarrays have been used to understand stage-specific differentiation [8][10], to determine invasion preferences [11],[12], and possibly pathogenesis [13][16].

At first, it was expected that DNA microarrays would also permit a quick, unbiased look at the mode of action of antimalarial drugs, particularly simple antimetabolites [17]. An underlying premise was that parasites would sense metabolic perturbations from a drug and make compensatory changes in its transcriptome to adjust for the perturbations. Indeed, studies in other organisms have demonstrated the value of such approaches. In Saccharomyces cerevisiae, Mycobacterium tuberculosis, Candida albicans, mammalian cells and even plants, specific antimetabolites up-regulated dozens of target-related RNA by greater than 10-fold [18][23]. In many of these systems confidence in the power of DNA microarrays to reveal mechanisms of drug action come from perturbation of well-understood metabolic pathways.

Our early preliminary studies had suggested that RNA levels for metabolic targets in malaria parasites are not sensitive to lethal antifolates nor to resulting specific metabolic perturbations [24][27]. Here, in a complete, carefully controlled microarray study, we definitively demonstrate that global gene expression in malaria parasites is regulated in a fundamentally different way from model organisms such as E. coli and yeast. Parasite transcription for intermediary metabolism is hard-wired and not responsive to specific, lethal, metabolic perturbations. We further demonstrate that candidate pathways involved in drug-induced death may still be identified through unconventional strategies, including probing for subtle RNA changes with a large number of replicates and tracking alterations in the hard-wired transcription program itself.


A defined experimental system

To guard against broad pleotropic transcriptional effects that may be difficult to interpret in drug-treated parasites, our study exploits the potency and specificity of the antifolate WR99210 against P. faciparum (Structure, Figure S1). The parasite clone Dd2 fails to proliferate when exposed to 10 nM WR99210 for 48 h [25], [28][30]. A concentration of 10 nM was selected because it is enough to kill all sensitive Dd2 cells (EC50 = 0.1 nM). Biochemical assays and genetic complementation studies (using human DHFR) have established P. falciparum DHFR-TS as the major target of WR99210 [25], [28][30].

To identify transcriptional changes that were directly related to death events caused by the lethal effects of WR99210 on DHFR, the present battery of microarray hybridizations included a control WR99210-resistant cell-line, B1G9, which harbors a single integrated copy of human DHFR in a Dd2 background [25],[29]. B1G9 is resistant to as much as 500 nM WR99210.

Finally, to help frame drug-induced changes in RNA levels in the context of cell physiology, Dd2 and B1G9 parasite lines were exposed to 10 nM WR99210 for varying time periods and the effects assessed with respect to clonal cell viability, continued synthesis of nucleic acids, RNA levels for individual genes coding for the effected pathways, and the global transcriptome.

Robust metabolism and development

A comparison of biochemical changes, morphological alterations and loss of cell viability in WR99210-treated Dd2 provided the first indication that malaria parasites resisted broad metabolic or developmental arrests in response to specific lethal perturbations. Using clonal viability as a measure of drug-induced death [31], 50% of P. falciparum trophozoites became less viable after as little as 6 h of exposure to 10 nM WR99210 (p<0.01) and practically all parasite cells were non-viable after 12 h of drug exposure (Figure 1A). However, even after 24 h of WR99210 treatment, trophozoites continued to follow a preordained metabolic program for converting short pulses of radioactive hypoxanthine into DNA, albeit with a lower amplitude (Figure 1B). Microscopic examination of WR99210-treated trophozoite forms of the parasite failed to show morphological changes until about 24 h after treatment when the schizonts appeared unhealthy (Figure 1C). At subsequent hours, control cells released merozoites and generated healthy rings but the WR99210-treated parasites remained as ill schizonts. In parallel assays, WR99210-resistant B1G9 cells behaved like untreated Dd2 (data not shown).

Figure 1
The antifolate WR99210 rapidly triggers commitment to death but fails to shut down metabolism or development.

Tracking genome-wide changes

In a single large controlled experiment, Plasmodium transcriptome changes were followed in WR99210-treated parasites using DNA microarrays with 7,685 oligonucleotide probes per slide, representing all open reading frames in the genome [4],[17]. For added value and confidence, the custom array also carried multiple probes per gene for key enzymes in the target pathway of folate and pyrimidine metabolism (Table S1 and S3). RNA samples from synchronized Dd2 and B1G9 trophozoites, that had been treated with 10 nM WR99210 for varying durations, were hybridized against a common pool of trophozoite RNA from a cognate clone (Figure 2A). For each time point, samples from biological duplicates were hybridized to four microarray slides, including dye exchanges. The biological duplicates were from independently propagated cultures to minimize misleading, stochastic variations in gene expression for surface proteins ([32], Figure S2 and Figure S3 for description of data normalization and variation between technical and biological variability). In total, the present normalized data is derived from 123 microarray hybridizations. As discussed below, this redundancy and accuracy was necessary to interpret some small but informative perturbations in RNA in P. falciparum. For some genes, it was possible to detect as little as 10–20% changes in RNA levels, with statistically significant reproducibility. Details of the experimental design, raw output, and statistical analysis are presented in MIAME-compliant format to the NIH-based GEO database (Accession # GSE9724 for WR99210 data from Seattle and # GSE9853 and # GSE9868 for the pyrimethamine data from Bangkok).

Figure 2
RNA for the antifolate target dihydrofolate reductase-thymidylate synthase is not overexpressed in WR99210-treated cells.

“Unresponsive” target pathways

During normal 48-hour developmental changes in erythrocytes, RNA levels for individual enzymes for pyrimidine and folate biosynthesis change nearly 10-fold [4]. During continual WR99210 treatment for 24 h, malaria parasites showed very little deviation in their transcriptome, even as they died from antifolate treatment.

First, expression of DHFR-TS, the immediate target of antifolates was examined in detail. Fluorescently labeled cDNA, generated from WR99210-treated and non-treated cells, was hybridized to 12 unique oligonucleotides derived from different parts of the 1,863 bp DHFR-TS coding strand (Figure 2A and 2B). Regardless of the WR99210-susceptibility status of the parasite clone, and regardless of whether the cells were treated with solvent or the antifolate, hybridization of fluorescent cDNA to most probes for DHFR-TS did not increase (and actually decreased slightly) during the 24 h normal progression of trophozoites to schizonts, (Figure 2D). Based on combined data from all 12 probes, RNA coding for DHFR-TS did not increase by more than 20% at any time point after WR99210-treatment (Figure 2C). This microarray-based analysis of DHFR-TS is consistent with earlier limited measurements using RNA Protection Assays (RPA) [25] and qRT-PCR [33]. For additional certainty, given recent description of differential expression of small regulatory RNA within the coding region of mammalian DHFR [34],[35], we undertook an independent detailed analysis of DHFR-TS expression using qRT-PCR spanning twelve different parts of the DHFR-TS coding region. As seen with the different unique oligonucleotide microarray probes (Figure 2D), qRT-PCR (Figure 2E–F) unambiguously confirmed that DHFR-TS RNA, or parts of DHFR-TS RNA, were not overproduced at protective levels in parasites treated with the lethal antimetabolite WR99210. Since the 10 nM WR99210 treatment was at 100-times the EC50 for Dd2 (0.1 nM), complete protection through increases in target RNA levels would require at least 100-fold increases in DHFR-TS RNA. Even a 10% protection from a RNA-based mechanism would require at least a 10-fold increase in DHFR-TS RNA.

Second, in addition to DHFR-TS, the expression of fourteen additional enzymes in the folate and pyrimidine biosynthesis pathways also did not deviate significantly from their normal transcriptional patterns. This analysis was based on at least two different microarray probes for each of the enzymes listed in Figure 3. The only two RNA species that showed small, consistent, significant changes from their normal expression program were serine hydroxymethyltransferase (SHMT) and a ribonucleotide reductase small subunit gene (RNR2). However, even these two responsive RNA species showed, at most, only a 2-fold change at very late time points (maximum 105% increase at 24 h, p<0.002). Even though the methylenetetrahydrofolate-using thymidylate synthase is thought to be the ultimate target of DHFR inhibition, the unresponsiveness of pyrimidine biosynthesis to DHFR-TS inhibitor have not previously been reported. Just as our preliminary microarray data had reported [24],[26],[27], a qRT-PCR study from an independent group has also shown that RNA for folate-biosynthesis enzymes are not up-regulated in response to pyrimethamine-treatment [33]. This other study did not look at changes in RNR2 and did not pickup the subtle drug-dependent alterations in transcripts for SHMT that are seen with the current large microarray data set.

Figure 3
As seen for DHFR-TS RNA levels, RNA for other enzymes in the folate and pyrimidine biosynthesis do not increase to high levels in WR99210-treated sensitive-parasites, Dd2.

“Unresponsive” genome

Given the inability of P. falciparum transcriptional program to overproduce RNA for DHFR-TS and related enzymes after antifolate treatment, we wanted to understand the extent of the overall transcriptional obstinacy in drug-sensitive parasites. In the first 3 h after WR99210 treatment, when death events were underway (p<0.05, Figure 1A), no genes showed statistically significant deviations from their normal developmental program that was greater than 2-fold in expression. Even 24 h after WR99210-treatment, when all cells are completely committed to die, greater than 99% of the genes in the Plasmodium transcriptome did not deviate significantly in gene expression.

Death-related “RNA whispers”

By exploiting our experimental design, which included side-by-side treatment of isogenic sensitive and resistant malaria parasite cell lines with a potent, specific, and lethal antifolate, it was possible to detect small reproducible changes in RNA in dying cells and only in dying cells.

Out of 7,685 oligonucleotides examined, there were 34 genes whose expression levels increased at least at one time point during the 24 h WR99210 study (Figure 4, and Table S4 for gene names, gene ID numbers, and fold-changes). There were 21 genes whose expression levels decreased at least at one time point (Figure 5 and Table S5). These changes were considered antifolate death-related genes (AFDG) because they were not seen in solvent-treated, drug-sensitive Dd2 parasites, and were not seen in solvent-treated or WR99210-treated resistant B1G9 cells.

Figure 4
Death-related up-regulated expression changes in WR99210-treated parasites.
Figure 5
Death-related down-regulated expression changes in WR99210-treated parasites.

The numerous death-related RNA changes were subtle and probably not protective, but they were statistically significant and possibly reflected larger physiologically important metabolic perturbations in dying parasite cells. The death-related transcripts provide the first insights into downstream events that may connect inhibition of DHFR-TS by antifolates to ultimate loss of cell viability (Table S4 and S5 for PlasmoDB gene numbers). Given the known mechanism of action of antifolates, the presence of ribonuceotide reductase and DNA repair endonuclease on this list was satisfying. The intriguing presence of putative cell-signaling proteins (phosphotyrosine phosphatase activator; a GTP binding protein; a Rab18 GTPase; and a calcium-dependent protein kinase) and some potential degradative enzymes (cysteine protease SERA3; protease; 20S proteosome beta 4) on the list of death-related genes should stimulate investigations of their possible role in antifolate toxicity. The list of death-related genes also included some known enzymes whose role in antifolate-mediated death is not obvious but should also be of interest (inorganic pyrophosphatase; gamma-glutamylcysteine synthetase; elongation factor Tu; and long-chain fatty acid ligase-oxalyl CoA decarboxylase). Finally, this genome-wide analysis revealed that, of the 55 antifolate-triggered small transcript changes, there were 25 hypothetical gene products with no previous known functions in other cell types.

Confirmation and cross-checks

To evaluate the validity and reliability of the small changes in RNA levels detected in the DNA microarray experiments, two different approaches were taken.

Conventional quantitative RT-PCR was used to compare RNA expression in independently cultivated P. falciparum Dd2 cells, before and after 10 nM WR99210 treatment for 24 h. This time point was used because the most significant changes on the microarray occurred after 24 h and the magnitude of the changes approached the resolution limits of RT-PCR. Out of 3 randomly chosen up-regulated genes, all 3 showed the expected small up-regulation upon WR99210 treatment (Table 1). Out of 3 randomly chosen down-regulated genes, 2 showed down-regulation as expected but one did not. Overall, we concluded that, though small, most RNA “whispers” picked up by the DNA microarrays were verifiable by qRT-PCR.

Table 1
qRT-PCR cross-check of representative microarray data.

In a completely different approach, two partner labs from two different parts of the world compared microarray data to determine if antifolate-treated parasites shared some common signatures in their transcriptome. Realistically, all the WR99210-reponsive genes from the Seattle study were not expected to show up in the Thailand study because the two groups were working with independently printed arrays, different parasites strains (Dd2 vs TM4/8.2), different antifolates (WR99210 vs pyrimethamine), and different treatment antifolate doses (99.9% vs 50% IC values). Yet, some of the most relevant changes should be shared, given the common mechanism of action of WR99210 and pyrimethamine. Indeed, a genome-wide comparison of transcript differences in antifolate-treated parasites versus solvent-treated parasites not only revealed 4 genes that were up-regulated and 5 genes that were down-regulated in concordance but the changes occurred at approximately the same time after antifolate treatment (Figure 6). In addition to some new proteins with no prior known functions, this set included a DNA repair endonuclease (MAL13P1.346) and a ubiquitin-conjugating enzyme (PF10_0330). It is not clear why the drug-induced down-regulation of RNA for the cytoadherance linked protein CLAG2 (PFB0935w) [36],[37] was seen in this set, but it appeared consistently in all other measures of antifolate toxicity in the present microarray study.

Figure 6
Independent DNA microarray-based confirmation of death-related expression changes in antifolate-treated parasites from two different labs.

Altered hard-wiring

It was hypothesized that even if a genetically determined hard-wired transcriptome is insensitive to real-time arrival of antimetabolites in the cell, perhaps the hard-wired program itself may evolve to tolerate an antimetabolite, particularly if given a chance to adapt over successive generations. Indeed, in the present large experiment with multiple controls, it was possible to identify genes whose expression in the resistant B1G9 cells was rewired in concordance with protection against the drug WR99210 (Figure 7 and Figure S4).

Figure 7
Adaptive changes in P. falciparum under long-term WR99210 exposure.

In this most compelling gene set, expression in the drug-resistant B1G9 cells behaved normally (as in non-treated, drug-sensitive Dd2 cells) only when B1G9 cells were under WR99210 pressure (Figure 7 and Table S6). In other words, expression of these genes was rewired so that it matched normal cells only when the antifolate WR99210 was present. The expression pattern of these genes was dissimilar in dying, drug-sensitive Dd2 cells exposed to WR99210, or resistant B1G9 cells grown without WR99210 (Figure 7). This data set included up-regulation of subtilisin-like protease 2 (PF11_0381) which might promote egress and reinvasion [38][42], an ADP-ribosylation factor-like protein (PFI1005w) [43],[44], and several “hypothetical proteins”. While detailed follow up studies will clearly be needed, the alteration in subtilisin-like protease expression ties nicely with morphological arrest of WR99210-treated parasites as ill schizonts and failure to see reinvasion and rings at later time points (Figure 1C).

A second set of permanent genetic alterations in the transcription program involved genes whose expression in the resistant B1G9 cells was different from the WR99210 sensitive Dd2, regardless of whether the antifolate was present or not (Figure S4 and Table S7). While it is possible that these genes also contribute to antifolate resistance mechanisms, this second data list should be accepted with caution since at least some of the RNA changes may have arisen through adventitious changes in the cell line due to collateral genetic damage during WR99210 adaptation.


Many commonly accepted paradigms for designing selective antimetabolites originate from the study of antifolates. Prior to the availability of genome sequences, mechanisms of drug action and the role of active site in selectivity were identified through intuitive comparisons to normal metabolites [45] and validation through resistance and transfection [46][48]. Our understanding of selective and potent antimetabolites continues to improve: Low, fixed levels of target enzyme in the parasite and the selective ability of host cells to overexpress target enzymes can play an important role in drug selectivity [25]. While useful, all such approaches have always relied on existing knowledge of biochemistry, metabolism, and pharmacology. Now, with the availability of genome sequences for Plasmodium parasites [49][51], and accompanying tools such as DNA microarrays [52],[53], there is much enthusiasm about using open ended tools to decipher drug action [17], particularly downstream biochemical and cellular events that lead to cell death.

First, the present study shows that WR99210 treatment of P. falciparum does not trigger overexpression of RNA for DHFR-TS, the known target of the antifolate (Figure 2). Casual observation of the microarray data clusters may suggest that DHFR-TS levels increase slightly. However, the color representations can be deceiving, in part because they are set at very high sensitivity (Figure 2D). The actual DHFR-TS increases are neither large nor statistically significant. While the follow up quantitative RT-PCR (Figure 2E and 2F) did show slightly higher levels of DHFR-TS RNA in treated cells, this was not due to RNA induction. The small “increases” in DHFR-TS RNA level in WR99210-treated Dd2 cells arise from a slight delays in normal degradation of DHFR-TS RNA, mostly at very late time points in the dying cell. When one asks the big question, do malaria parasites overexpress the target DHFR-TS RNA to protective levels when treated with the antifolate WR99210? The answer is clearly negative. Can DNA microarrays be used to unambiguously assign mechanisms of antifolate action through real-time changes in RNA levels after drug exposure? The answer, again, is unambiguously negative.

Beyond the immediate target DHFR-TS, the parasites also do not overproduce RNA for any of the enzymes of pyrimidine or folate metabolism, two pathways known to be effected by antifolates (Figure 3). Most importantly, long after P. falciparum cells treated with WR99210 were committed to death, there were no large consistent reliable increases in RNA for any of the genes in the P. falciparum genome. The last observation shows that the transcriptional obstinacy of P. falciparum is not just restricted to folate biochemistry but permeates through much of the parasite's metabolic network involved in control of cell proliferation, and eventually cell death. Since this large project started and has been reported in preliminary form at scientific meetings, several other smaller DNA microarray studies have also encountered transcriptomes resistance to antimetabolites. This includes work on the antimalarial choline analogue T4, the mitochondrial inhibitor atovaquone, and most recently the polyamine biosynthesis inhibitor DFMO [54][56]. Earlier claims that malaria parasites show specific large transcriptional responses to chloroquine [57], were reversed [58]. The later conclusion appears to be correct since an independent study has also recently claimed a lack of real-time changes in RNA levels in chloroquine-treated P. falciparum [59]. Doxycycline a protein synthesis inhibitor for subcellular organelles caused a whole-sale shutdown of apicoplast RNA, not specific up-regulation of RNA for the target protein [60]. The emerging general consensus is that malaria parasites do not mount large increases in RNA in response to antimetabolites. Our conclusions from the original discovery using antifolates remains compelling because the study uses a potent, specific inhibitor (WR99210) that targets a genetically validated target (DHFR): Drugs with broad or poorly defined mechanism of action were avoided because they can add to existing uncertainty about malarial transcriptional responses.

Even though large protective changes in RNA were not seen in drug-treated malaria parasites, the tightly controlled nature of the present study led to unbiased glimpses into small, subtle downstream RNA changes in drug treated malaria parasites. One type of change involved small, reproducible real-time changes in RNA in sensitive cells and only in the sensitive cells (Figure 3, ,44 and and5).5). These include RNA coding for proteins involved in relevant target pathways: ribonucleotide reductase of nucleotide metabolism and serine hydroxymethyltransferase of folate metabolism. In addition, there were dozens of new genes whose expression was perturbed and whose role in folate pharmacology would be new and unexpected, including enzymes involved in DNA replication, cell signaling, and protein turnover. Secondly, while the hard-wired transcription for metabolic genes in malaria parasites was largely unresponsive to drug-treatment in real-time, the hard-wiring program itself could evolve in a population that is under continual drug pressure. Such alterations in the transcriptomes offer glimpses into new biochemistry related to drug action (Figure 7). The last finding presents a clear caution to malaria scientists who rely heavily on DNA transfections to study drug action. Transfection of the malarial parasite line Dd2 with single copy of the human DHFR originally proved the primary mechanism of action of WR99210 [29]. However, emergence of transformants always involve long delay phases, very similar to those seen during in vitro selection for drug resistance in the laboratory [61],[62]. It is very likely that while human DHFR helps confer resistance to WR99210, additional genetic changes in the hard-wiring of gene expression are necessary to fully realize the WR99210 tolerance and optimum growth in the transformed cell. Identification of these secondary genetic changes are expected to be fertile grounds for fully understanding downstream biochemical changes that lead from DHFR-TS inhibition to cell toxicity.

The present findings add some general rules to help us understand how some good antimalarial drugs work. First, as gene amplification can contribute to drug resistance [63], unconditional suppression of target protein and RNA for metabolic enzymes may contribute to unusual vulnerabilities in the parasite. Previously, P. falciparum DHFR-TS protein was shown to bind its cognate RNA sequence differently than the host protein [25]. Now we show that the production of RNA itself may be severely limited and this repression of transcription is largely insensitive to metabolic changes. Second, in principle, while natural metabolites and their toxic homologues may not induce large scale changes in target gene expression in malaria parasites, it is conceivable that some other antimalarial molecules could exhibit broad toxicity, in part, by misdirecting the hard-wired transcriptional program of P. falciparum. Third, if there is limited flexibility in regulating gene-expression, perturbations by drugs must be balanced by compensating mutations affecting the transcriptome [64]. This would influence frequencies of drug resistance in unpredictable ways [62],[65], as well as leave molecular footprints of prior drug exposure throughout the genome [66],[67].

The evolutionary implications of the hard-wired malaria parasite transcriptome to control metabolism are significant. Parasites appear to have at least two fundamentally different strategies for gene regulation: Alterations in expression of genes for surface proteins occur randomly to help parasites “outmaneuver” unpredictable immune responses from each new host the parasite encounters [68][70]. In contrast, for intermediary metabolism, the obligatory parasites seem to have evolved a deterministic transcriptional program to match the defined and predictable biochemical makeup of host cells. Compared to variations in immune responses, the biochemical environment between different host individuals probably does not vary significantly. The biochemical adaptations which accompany these evolutionary choices in gene regulation must be significant. A priori, the systematic, sequential, rhythmic expression of metabolic genes in malaria parasites must be determined by a sequential expression of regulatory molecules which are largely insensitive to intracellular levels of important metabolites. Of course, while such a model could apply to repeated erythrocytic cycles, it need not preclude a signal-based strategy for influencing differentiation of parasites.

Materials and Methods

DNA microarrays for P. falciparum

The present experiments used spotted DNA microarrays [71] that were fabricated as previously described [9],[32]. Commercially available malaria oligonucleotides (Operon, version 1.1, https://www.operon.com/arrays/oligosets_malaria.php) were combined with in-house oligonucleotides representing P. falciparum genes in folate and nucleic acid metabolism. The in-house oligos were designed at the University of Washington using ArrayOligoSelector [52] and synthesized by Operon Biotechnologies, Inc. The arrays, each representing the majority of malarial open reading frames plus the custom oligonucleotides, were printed on polylysine-coated slides using an ultra fast, linear servo driven DeRisi microarrayer. Slides were post-processed and hybridized following the protocols as previously described (http://cmgm.stanford.edu/pbrown/protocols/index.html). Each platform used in the following experiments is described and can be accessed at the NIH-based GEO database (Accession # GPL6187 for WR99210 data from Seattle and # GPL6187 and # GPL6269 for the pyrimethamine data from Bangkok).


At the University of Washington, Seattle, WA, P. falciparum clones Dd2 and B1G9 were used for treatment with WR99210. Clone Dd2 was derived from clone W2 from Southeast Asia and is resistant to a variety of antimalarials, but not WR99210 [25],[65],[72]. The isogenic clone B1G9, which harbored a single integrated copy of human DHFR in a Dd2 background, conferred resistance to WR99210 and was kindly provided by Drs. David Fidock and Thomas Wellems [25],[29]. At the National Center for Genetic Engineering and Biotechnology (BIOTEC), Bangkok, Thailand, a pyrimethamine-sensitive laboratory clone TM4/8.2 was treated with pyrimethamine prior to microarray analysis. The TM4/8.2 clone was obtained from Dr Sodsri Thaithong, Chulalongkorn University, Thailand. At both sites, parasites were cultured in vitro by standard methods [73].

Clonal viability

Clonal viability of WR99210-treated parasites was based on a previously established assay [31]. Forty 10 ml cultures, with synchronized early-trophozoite forms of infected erythrocytes, were treated for different durations with 10 nM WR99210 in a final concentration of 0.1% DMSO. Treatment times ranged from 3 h to 24 h, with two flasks per time-point. At appropriate times, cells from each flask were washed and clonally diluted in drug-free medium. Representative dilutions from each flask were plated at a density of about one infected erythrocyte per well in 24 wells of a 96-well plate (4 samples per time point). Growth in each well was monitored microscopically in drug-free medium for two to four weeks. On average, 20 “colonies” (i.e. parasite containing wells) were identified from solvent treated, time-zero parasite populations.

Rates of DNA metabolism

Trophozoite forms of infected erythrocytes in ten ml cultures were incubated with 10 nM WR99210 for 1–24 h and then pulsed with radioactive hypoxanthine (2 µCi per flask, 22 mCi/umol) for one hour prior to collection of precipitable radioactive DNA on glass fiber filters. In the absence of drug treatment, maximum incorporation was seen at 4–10 h into trophozoite development (approximately 5,000 cpm; 500 pmol/flask).

Drug treatment and RNA extraction

Overall, in Seattle, for the master DNA microarray experiment, two large populations of Dd2 cells and two large populations of B1G9 cells were prepared for treatment with WR99210. Dd2 clones, starting with about 100 infected erythrocytes per flask, were setup in 60 flasks and propagated until 30 ml cultures were established at 5% parasitemia, 2% hematocrit in each flask. These independently propagated parasites were pooled and redistributed into 60 flasks before drug treatment (see below). A second set of biological replicates of Dd2 were propagated, pooled, and split independently to give two truly independent populations of Dd2. The overall goal was to neutralize stochastic changes in gene expression for surface proteins [32]. This whole exercise was repeated separately with clone B1G9.

To describe the details of the parasite preparation, in each set above (each biological replicate of Dd2 or B1G9), parasites were initially seeded in 10 ml cultures with about 100 infected erythrocytes per flask. When parasitemia reached about 5%, the cells were transferred to 30 ml cultures. When parasitemia reached 5% in each 30 ml culture the first time, the infected cells were synchronized with 5% sorbitol [74]. When parasitemia reached 5% again, and when most of the infected erythrocytes were in the ring stage, the synchronization was repeated once more. These parasites (in one set) were pooled and redistributed into 30 ml flasks, until they reached early trophozoite stage. Half of these samples were saved as “Time zero, trophozoites” and served as reference RNA for the time-course experiments. Of the remaining parasites, half the 30 ml flasks were treated with 10 nM WR99210 (1∶1,000 dilution of 10 µM WR99210 stock in 100% DMSO) and the other half were treated with solvent (final concentration of 0.1% DMSO). At various time-points (3 h to 24 h), infected erythrocytes were centrifuged down, and parasites were released by saponin treatment [75]. After two washes in PBS, the parasites were resuspended in lysis buffer (RNAqueouse Kit, Ambion) and RNA was isolated according to the manufacturer's instructions. As discussed above, 2 preparations of independently derived Dd2 were treated with solvent or with 10 nM WR99210. Similarly, 2 preparations of independently propagated B1G9 were treated with DMSO solvent or with 10 nM WR99210.

In Thailand, for each treatment, three 30 ml culture plates (90×15 mm) of TM4/8.2 parasites were set up at 4% hematocrit and 7–10% parasitemia. After two rounds of synchronization, an early trophozoites culture (approximately at 18–20 h post invasion) was treated with 0.5 µM pyrimethamine. The final concentration of DMSO solvent in each treatment was 0.1%. A culture containing 0.1% DMSO lacking drug was used as a control. After 2 h, 4 h, 8 h and 24 h of drug exposure, parasites were collected and extracted from erythrocytes by saponin lysis. Total RNA was purified from parasite cells using Trizol reagent (Invitrogen) according to the manufacturer's instructions. Experimental treatments were carried out from at least two independent cultures to wash out stochastic biological variation.

For RT-PCR based confirmation experiments, appropriate clones of independently seeded parasites were grown in 10 ml cultures and RNA was collected by RNAqueouse Kit (Ambion) according to the manufacturer's instructions. Contaminating DNA was removed from the total RNA samples using RQ1 RNase-Free DNase (Promega).

Fluorescent cDNA preparation and hybridization

For each hybridization, 10 µg of total RNA was annealed with 5 µg pd(N)6 random primers (Amersham Biosciences Corp.) and reverse transcribed to produce aminoallyl-dUTP (Sigma)-labelled cDNA using StrataScript reverse transcriptase (Stratagene). Oligo-(dT)21 primer was used instead of the random hexamer for pyrimethamine treated samples from Thailand. The labelled cDNAs were coupled with either monoreactive-Cy3 or -Cy5 (Amersham Biosciences) as previously described [32]. Purified Cy3- and Cy5-labelled cDNAs were resuspended and mixed in 24 µl of hybridization solution containing 3× SSC, 0.2% SDS, 0.025 M HEPES and 0.75 µg/µl of poly A (Sigma) and hybridized on a P. falciparum 70-mer microarray for 16 h at 63°C.

Data collection and analysis

After washing, slides were scanned in an Axon GenePix 4000B microarray scanner and the intensity of spots was quantified using GenePix Pro 3.0 Software (Axon Instruments, Inc.) as previously described [32]. Briefly, during the gridding process, images were inspected and visually problematic spots were manually flagged and removed. Spots with foreground intensity less than 2.1-fold of background intensity were considered too weak to be reliable and also removed. A scaled print-tip intensity-dependent lowess within-slide normalization was performed on each slide, followed by an across-slides normalization, using Aroma package version 0.89 [76] run in R project environment (http://cran.r-project.org). Differential expression and statistical analysis of Seattle data were done using a linear model method package Limma [77]. The criteria of the p-value of <0.05 and expression ratio≥2-fold change were employed for selection of differentially expressed genes. For Thailand data, statistically significant differences in gene expression were monitored using the Significance Analysis of Microarrays (SAM) program [78] and genes showing false discovery rate (FDR) = 0% and expression ratio of ≥1.5-fold in both directions were considered differentially expressed. Cluster analysis was performed using CLUSTER and visualized using TREEVIEW [79].

Quantitative RT-PCR confirmation

Six of AFDG genes whose ratio of SD/SS was greater than 2 at 24 h of WR99210 exposure were selected for qRT-PCR validation. These were PFD1120c, PF10_0330, PFC0710w, PFB0915w, PFB0635w and MAL6P1.231. Three hundred nanograms of total RNA was primed with Oligo(dT)/random nanomers mix (at final concentration of 100 ng each/reaction) and converted to cDNA in 20 µl reactions using AffinityScript™ QPCR cDNA synthesis kit (Stratagene) as recommended by the manufacturer. The reverse transcription reaction was then diluted with 40 µl of nuclease-free PCR-grade water before using in the PCR amplification step. Real-time quantitative PCR was performed on a thermal cycler (DNA Engine, BioRad) equipped with a detector (Chromo4, BioRad). Primers were designed using PRIMER3 (http://www-genome.wi.mit.edu/genome_software/other/primer3.html) and optimized for annealing/extension temperature, concentration, and single product amplification. The designed primers are listed in Table S2. Amplifications were performed in 25 µl final volume, using 12.5 µl of 2× Brilliant® SYBR® Green QPCR Master Mix (Stratagene), 2 µl of the cDNA template, and 250 nM of each primer. Cycling conditions were: 10 min at 95°C and 40 cycles of 95°C for 15 sec followed by 58°C for 60 sec. The specificity of the amplifications was monitored by melting curve analysis and gel electrophoresis. The threshold cycle of fluorescence (Ct) was determined by Opticon Monitor 3 software (BioRad). The quantity of cDNA for each gene was normalized to the Seryl-tRNA synthetase (PF07_0073) concentration in each sample (ΔCt, Ctgene−CtPF07_0073). Relative gene expression was calculated by 2−ΔΔCt method [80], where ΔΔCt is the ratio of expression of each treatment relative to that of the trophozoite stage reference. Each PCR experiment was performed in duplicates with at least three RNA templates prepared from independent parasite cultures.

Analysis of the DHFR-TS oligos was performed with slight modifications to the procedure described above. Two hundred seventy nanograms of total RNA was used per cDNA synthesis reaction and then diluted with 25 µL of nuclease-free PCR-grade water. The annealing/extension temperature was reduced to 56°C. Analysis was performed using the Pfaffl method [81] with each primer pair's efficiency taken into account. Each experiment was performed in triplicate and the 24 h time-point was analyzed in three independent cultures. A representative run is shown and plotted error bars are the SEM of that run.

Supporting Information

Figure S1

Structures of antifolates used to study changes in transcript levels in malaria parasites. (A) WR99210 used by the Seattle lab against sensitive clone Dd2 and resistant clone B1G9 carrying human DHFR. (B) Pyrimethamine used by the Bangkok lab against the sensitive clone TM4/8.2.

(0.24 MB TIF)

Figure S2

(A) Representative M-A plot of raw microarray data from SD24_rep1. In the analysis, data was derived from microarrays in which RNA from WR99210-treated (Cy5) parasite and RNA from reference pool (Cy3) control were compared. Raw data in the form of relative fluorescence intensity were log transformed and used to calculate M (difference in log intensities) and A (average log intensity) for each spot on the microarray. Most spots cluster around the zero line. Red and green spots indicate an M value of higher and lower than 1, respectively. (B) M-A plot of scaled print-tip and across slide normalized data. (C) Box-plot before normalization. (D) Box-plot of scaled print-tip and across slide normalized data.

(0.93 MB TIF)

Figure S3

Log2 (WR99210-treated/reference pool) comparison between replicates of representative experiment (SD24). (A) Log2 expression ratio comparison between SD24_rep1 and SD24_rep3 (technical replicate). SD24_rep3 is a dye swap experiment of SD24_rep1. (B) Log2 expression ratio comparison between SD24_rep1 and SD24_rep2 (biological replicate). (C) Log2 expression ratio comparison between SD24_rep1 and SD24_rep4 (biological replicate). SD24_rep4 is a dye swap experiment of SD24_rep2. Correlation between replicates demonstrates the high degree of reproducibility of the data, but biological replicates show greater variability in part due to stochastic changes in surface gene expression.

(0.46 MB TIF)

Figure S4

Genes whose expression changed permanently in resistant clone B1G9 comparing to sensitive clone Dd2 (with or without drug pressure). Each probe was tested for changes in expression in 4 comparisons (SS vs RS, SD vs RS, SS vs RD, and SD vs RD) at each time point. Probes were selected against these comparisons jointly, with multiple testing adjusted p<0.01.

(0.47 MB TIF)

Table S1

(0.01 MB PDF)

Table S2

(0.08 MB PDF)

Table S3

(0.03 MB XLS)

Table S4

(0.07 MB XLS)

Table S5

(0.05 MB XLS)

Table S6

(0.05 MB XLS)

Table S7

(0.05 MB XLS)


The authors are most thankful to Joseph DeRisi at the University of California San Francisco and his colleagues, Adam Carol and Manuel Llinas (currently at Princeton University), for malaria-specific long oligonucleotides, assembly of our robotic arrayer, and technical advice.


The authors have declared that no competing interests exist.

The Seattle scientists acknowledge support from the University of Washington (UW) Royalty Research Fund, The UW Keck Center for Microbial Pathogens, and the US National Institutes of Health (AI26912 and AI60360). PKR has a Senior Scholar Award in Global Infectious Diseases from the Ellison Medical Foundation. The Bangkok scientists received support from the Thailand Research Fund through the Royal Golden Jubilee Ph.D. Program (Grant No. PHD/0126/2544 to PW and NP). In addition, The Wellcome Trust, the Medicines for Malaria Venture (MMV) Program and UNICEF/UNDP/World Bank/WHO Special Program on Tropical Diseases supported YY and SK. SK is also an international scholar of the Howard Hughes Medical Institute (HHMI, USA).


1. Miller LH. Malaria–a shadow over Africa. Science. 2002;298:121–122. [PubMed]
2. Breman JG. The intolerable burden of malaria: a new look at the numbers. Am J Trop Med Hyg. 2001;64:iv–vii. [PubMed]
3. Guerra CA, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med. 2008;5:e38. doi:10.1371/journal.pmed.0050038. [PMC free article] [PubMed]
4. Bozdech Z, et al. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol. 2003;1:e5. doi:10.1371/journal.pbio.0000005. [PMC free article] [PubMed]
5. Le Roch KG, et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science. 2003;301:1503–1508. [PubMed]
6. Ben Mamoun C, et al. Co-ordinated programme of gene expression during asexual intraerythrocytic development of the human malaria parasite Plasmodium falciparum revealed by microarray analysis. Mol Microbiol. 2001;39:26–36. [PubMed]
7. Llinas M. Comparative whole genome transcriptome analysis of three Plasmodium falciparum strains. Nucleic Acids Res. 2006;34:1166–1173. [PMC free article] [PubMed]
8. Hall N, et al. A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science. 2005;307:82–86. [PubMed]
9. Hayward RE, et al. Shotgun DNA microarrays and stage-specific gene expression in Plasmodium falciparum malaria. Mol Microbiol. 2000;35:6–14. [PubMed]
10. Silvestrini F, et al. Genome-wide identification of genes upregulated at the onset of gametocytogenesis in Plasmodium falciparum. Mol Biochem Parasitol. 2005;143:100–110. [PubMed]
11. Stubbs J, et al. Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science. 2005;309:1384–1387. [PubMed]
12. Shi Q, et al. Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites. Infect Immun. 2005;73:6363–6371. [PMC free article] [PubMed]
13. Schaecher K. Genome-wide expression profiling in malaria infection reveals transcriptional changes associated with lethal and nonlethal outcomes. Infect Immun. 2005;73:6091–6100. [PMC free article] [PubMed]
14. Lovegrove FE, et al. Simultaneous host and parasite expression profiling identifies tissue-specific transcriptional programs associated with susceptibility or resistance to experimental cerebral malaria. BMC Genomics. 2006;7:295. [PMC free article] [PubMed]
15. Siau A, et al. Whole-transcriptome analysis of Plasmodium falciparum field isolates: identification of new pathogenicity factors. J Infect Dis. 2007;196:1603–1612. [PubMed]
16. Delahaye NF, et al. Gene expression analysis reveals early changes in several molecular pathways in cerebral malaria-susceptible mice versus cerebral malaria-resistant mice. BMC Genomics. 2007;8:452. [PMC free article] [PubMed]
17. Rathod PK. DNA microarrays for malaria. Trends Parasitol. 2002;18:39–45. [PubMed]
18. Bammert GF. Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob Agents Chemother. 2000;44:1255–1265. [PMC free article] [PubMed]
19. Boshoff HI, et al. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem. 2004;279:40174–40184. [PubMed]
20. De Backer MD, et al. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob Agents Chemother. 2001;45:1660–1670. [PMC free article] [PubMed]
21. Wilson M, et al. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A. 1999;96:12833–12838. [PMC free article] [PubMed]
22. Maxwell PJ, et al. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res. 2003;63:4602–4606. [PubMed]
23. Bassel GW, et al. Elucidating the germination transcriptional program using small molecules. Plant Physiol 2008 [PMC free article] [PubMed]
24. Rathod PK. Microarray analysis of Plasmodium Drug responses. 2002. ACMCI Symposium on Molecular Parasitology 51st ASTMH Annual Meeting. Denver, CO.
25. Zhang K. Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science. 2002;296:545–547. [PMC free article] [PubMed]
26. Rathod PK. Identification of novel targets for antimalarial drugs. 2003. British Society of Parasitology Meeting. Manchester, UK. ( http://www.fems.org.uk/meetings/pdfabstracts/umist2003abs.pdf)
27. Ganesan K. Rigidity of the Plasmodium transcriptome revealed by a lethal antifolate. 2003. Molecular Parasitology Meeting. Woods Hole, MA. ( http://www.mbl.edu/mpm/mpm-2003/abstracts/index.php)
28. Canfield CJ, et al. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg. 1993;49:121–126. [PubMed]
29. Fidock DA. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997;94:10931–10936. [PMC free article] [PubMed]
30. Hekmat-Nejad M. Plasmodium falciparum: kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase. Exp Parasitol. 1997;87:222–228. [PubMed]
31. Young RD. Clonal viability measurements on Plasmodium falciparum to assess in vitro schizonticidal activity of leupeptin, chloroquine, and 5-fluoroorotate. Antimicrob Agents Chemother. 1993;37:1102–1107. [PMC free article] [PubMed]
32. Ganesan K. Stochastic versus stable transcriptional differences on Plasmodium falciparum DNA microarrays. Int J Parasitol. 2002;32:1543–1550. [PubMed]
33. Nirmalan N. Transcriptional analysis of genes encoding enzymes of the folate pathway in the human malaria parasite Plasmodium falciparum. Mol Microbiol. 2002;46:179–190. [PubMed]
34. Mishra PJ, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A. 2007;104:13513–13518. [PMC free article] [PubMed]
35. Martianov I. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature. 2007;445:666–670. [PubMed]
36. Iriko H, et al. Diversity and evolution of the rhoph1/clag multigene family of Plasmodium falciparum. Mol Biochem Parasitol. 2008;158:11–21. [PMC free article] [PubMed]
37. Kaneko O, et al. Apical expression of three RhopH1/Clag proteins as components of the Plasmodium falciparum RhopH complex. Mol Biochem Parasitol. 2005;143:20–28. [PubMed]
38. Hackett F. PfSUB-2: a second subtilisin-like protein in Plasmodium falciparum merozoites. Mol Biochem Parasitol. 1999;103:183–195. [PubMed]
39. Miller SA. TgSUB2 is a Toxoplasma gondii rhoptry organelle processing proteinase. Mol Microbiol. 2003;49:883–894. [PubMed]
40. Harris PK, et al. Molecular identification of a malaria merozoite surface sheddase. PLoS Pathog. 2005;1:e29. doi:10.1371/journal.ppat.0010029. [PMC free article] [PubMed]
41. Barale JC, et al. Plasmodium falciparum subtilisin-like protease 2, a merozoite candidate for the merozoite surface protein 1–42 maturase. Proc Natl Acad Sci U S A. 1999;96:6445–6450. [PMC free article] [PubMed]
42. Green JL. Plasmodium thrombospondin related apical merozoite protein (PTRAMP) is shed from the surface of merozoites by PfSUB2 upon invasion of erythrocytes. Mol Biochem Parasitol. 2006;150:114–117. [PubMed]
43. Truong RM. Cloning and characterization of Plasmodium falciparum ADP-ribosylation factor and factor-like genes. Mol Biochem Parasitol. 1997;84:247–253. [PubMed]
44. Stafford WH. Isolation, expression and characterization of the gene for an ADP-ribosylation factor from the human malaria parasite, Plasmodium falciparum. Eur J Biochem. 1996;242:104–113. [PubMed]
45. Ferone R. Plasmodium berghei dihydrofolate reductase. Isolation, properties, and inhibition by antifolates. Mol Pharmacol. 1969;5:49–59. [PubMed]
46. Wu Y. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc Natl Acad Sci U S A. 1996;93:1130–1134. [PMC free article] [PubMed]
47. McCutchan TF, et al. Mechanism of pyrimethamine resistance in recent isolates of Plasmodium falciparum. Antimicrob Agents Chemother. 1984;26:656–659. [PMC free article] [PubMed]
48. Crabb BS. Characterization of promoters and stable transfection by homologous and nonhomologous recombination in Plasmodium falciparum. Proc Natl Acad Sci U S A. 1996;93:7289–7294. [PMC free article] [PubMed]
49. Gardner MJ, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002;419:498–511. [PMC free article] [PubMed]
50. Carlton JM, et al. Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature. 2002;419:512–519. [PubMed]
51. Carlton J. The Plasmodium vivax genome sequencing project. Trends Parasitol. 2003;19:227–231. [PubMed]
52. Bozdech Z, et al. Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. Genome Biol. 2003;4:R9. [PMC free article] [PubMed]
53. Le Roch KG. Monitoring the chromosome 2 intraerythrocytic transcriptome of Plasmodium falciparum using oligonucleotide arrays. Am J Trop Med Hyg. 2002;67:233–243. [PubMed]
54. Painter HJ. Early response to antimalarial drug treatment examined by whole genome transcription profiling. 2004. Molecular Parasitology Meeting. Woods Hole, MA. ( http://www.mbl.edu/mpm/mpm-2004/abstracts/abstract.php?id=161)
55. Le Roch KG, et al. Functional genomics of the antimalarial choline analogue T4 on Plasmodium falciparum, reveal potential therapeutic targets. 2004. Molecular Parasitology Meeting. Woods Hole, MA. ( http://www.mbl.edu/mpm/mpm-2004/abstracts/abstract.php?id=257)
56. Clark K. Transcriptional responses of Plasmodium falciparum to alpha-difluoromethylornithine-induced polyamine depletion. Biol Chem. 2008;389:111–125. [PubMed]
57. Gunasekera AM. Drug-induced alterations in gene expression of the asexual blood forms of Plasmodium falciparum. Mol Microbiol. 2003;50:1229–1239. [PubMed]
58. Gunasekera AM. Plasmodium falciparum: genome wide perturbations in transcript profiles among mixed stage cultures after chloroquine treatment. Exp Parasitol. 2007;117:87–92. [PubMed]
59. Jiang H, et al. Genome-wide compensatory changes accompany drug- selected mutations in the Plasmodium falciparum crt gene. PLoS ONE. 2008;3:e2484. doi:10.1371/journal.pone.0002484. [PMC free article] [PubMed]
60. Dahl EL, et al. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006;50:3124–3131. [PMC free article] [PubMed]
61. Rathod PK. Selection and characterization of 5-fluoroorotate-resistant Plasmodium falciparum. Antimicrob Agents Chemother. 1994;38:2871–2876. [PMC free article] [PubMed]
62. Gassis S. Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance. Antimicrob Agents Chemother. 1996;40:914–919. [PMC free article] [PubMed]
63. Beverley SM. Gene amplification in Leishmania. Annu Rev Microbiol. 1991;45:417–444. [PubMed]
64. Waller KL, et al. Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter. J Biol Chem. 2003;278:33593–33601. [PubMed]
65. Rathod PK. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A. 1997;94:9389–9393. [PMC free article] [PubMed]
66. Volkman SK, et al. A genome-wide map of diversity in Plasmodium falciparum. Nat Genet. 2007;39:113–119. [PubMed]
67. Gonzales JM, et al. Regulatory Hotspots in the Malaria Parasite Genome Dictate Transcriptional Variation. PLoS Biol. 2008;6:e238. doi:10.1371/journal.pbio.0060238. [PMC free article] [PubMed]
68. Horrocks P. Variable var transition rates underlie antigenic variation in malaria. Proc Natl Acad Sci U S A. 2004;101:11129–11134. [PMC free article] [PubMed]
69. Su XZ, et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell. 1995;82:89–100. [PubMed]
70. Hommel M. Surface alterations of erythrocytes in Plasmodium falciparum malaria. Antigenic variation, antigenic diversity, and the role of the spleen. J Exp Med. 1983;157:1137–1148. [PMC free article] [PubMed]
71. Brown PO. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999;21:33–37. [PubMed]
72. Oduola AM. Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Exp Parasitol. 1988;67:354–360. [PubMed]
73. Trager W. Human malaria parasites in continuous culture. Science. 1976;193:673–675. [PubMed]
74. Lambros C. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979;65:418–420. [PubMed]
75. Rathod PK. Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum. Antimicrob Agents Chemother. 1992;36:704–711. [PMC free article] [PubMed]
76. Bengtsson H. aroma – An R Object-oriented Microarray Analysis environment. 2004. [ http://www.maths.lth.se/publications/].
77. Smyth GK. Limma: Linear models for microarray data. In: Gentleman R, editor. Bioinformatics and Computational Biology Solutions using R and Bioconductor. New York: Springer; 2005. pp. 397–420.
78. Tusher VG. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116–5121. [PMC free article] [PubMed]
79. Eisen MB. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863–14868. [PMC free article] [PubMed]
80. Livak KJ. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. [PubMed]
81. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45. [PMC free article] [PubMed]

Articles from PLoS Pathogens are provided here courtesy of Public Library of Science
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • BioProject
    BioProject links
  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • GEO DataSets
    GEO DataSets
    Gene expression and molecular abundance data reported in the current articles that are also included in the curated Gene Expression Omnibus (GEO) DataSets.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
  • Taxonomy
    Taxonomy records associated with the current articles through taxonomic information on related molecular database records (Nucleotide, Protein, Gene, SNP, Structure).
  • Taxonomy Tree
    Taxonomy Tree

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...